Indication
X-linked hypophosphatemic osteomalacia
X-linked hypophosphatemic osteomalacia is a rare, hereditary metabolic bone disorder representing the adult skeletal manifestation of X-linked hypophosphatemia. Read more about X-linked hypophosphatemic osteomalacia
44 drugs 39 manufacturers
Drugs that treat it
Common X-linked hypophosphatemic osteomalacia therapies.
VITAMIN D2 (ergocalciferol (vitamin D2))
VITAMIN D2 (ergocalciferol (vitamin D2))
VITAMIN D2 (ergocalciferol (vitamin D2))
VITAMIN D2 (ergocalciferol (vitamin D2))
VITAMIN D2 (ergocalciferol (vitamin D2))
ERGOCALCIFEROL (VITAMIN D2)
ERGOCALCIFEROL (VITAMIN D2)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonX-linked hypophosphatemic osteomalacia is a rare, hereditary metabolic bone disorder representing the adult skeletal manifestation of X-linked hypophosphatemia.
It primarily affects skeletally mature adolescents and adults, driven by loss-of-function variants in the *PHEX* gene that lead to excessive circulating fibroblast growth factor 23 (FGF23).
This excess hormone induces renal phosphate wasting and impairs active vitamin D synthesis, resulting in chronic hypophosphatemia and defective mineralization of mature bone matrix.
Clinically, affected patients present with generalized bone pain, persistent muscle weakness, pseudofractures, increased fracture susceptibility, early-onset enthesopathies, and impaired physical mobility.
- nih.gov
X-linked hypophosphatemic osteomalacia is a rare, hereditary metabolic bone disorder representing the adult skeletal manifestation of X-linked hypophosphatemia It primarily affects skeletally mature adolescents and adults, driven by loss-of-function variants in the *PHEX* gene that lead to excessive circulating fibroblast growth factor 23 (FGF23)
- childrenshospital.org
X-linked hypophosphatemic osteomalacia is a rare, hereditary metabolic bone disorder representing the adult skeletal manifestation of X-linked hypophosphatemia
- caresource.com
It primarily affects skeletally mature adolescents and adults, driven by loss-of-function variants in the *PHEX* gene that lead to excessive circulating fibroblast growth factor 23 (FGF23) Clinically, affected patients present with generalized bone pain, persistent muscle weakness, pseudofractures, increased fracture susceptibility, early-onset enthesopathies, and impaired physical mobility
- crysvitahcp.com
This excess hormone induces renal phosphate wasting and impairs active vitamin D synthesis, resulting in chronic hypophosphatemia and defective mineralization of mature bone matrix
- endocrine.org
This excess hormone induces renal phosphate wasting and impairs active vitamin D synthesis, resulting in chronic hypophosphatemia and defective mineralization of mature bone matrix Clinically, affected patients present with generalized bone pain, persistent muscle weakness, pseudofractures, increased fracture susceptibility, early-onset enthesopathies, and impaired physical mobility
- medlineplus.gov
Clinically, affected patients present with generalized bone pain, persistent muscle weakness, pseudofractures, increased fracture susceptibility, early-onset enthesopathies, and impaired physical mobility
Personalize your experience
Follow X-linked hypophosphatemic osteomalacia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.